Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederic Bouder

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Drug Safety|April 11, 2015
Risk communication of vaccines: challenges in the post-trust environmentFrederic Bouder
Expert Review of Clinical Pharmacology|January 16, 2014
Regulating impurities in pharmaceutical products: a tolerability of risk approach?Frederic Bouder
Expert Review of Clinical Pharmacology|January 16, 2014
Tolerability of risk approach and the management of pharmaceutical risksFrederic Bouder, Ragnar Löfstedt
Current Drug Safety|May 10, 2013
The future of risk communication and the role of the pharmaceutical industrySweta Chakraborty, Frederic Bouder
Journal of Health Communication|November 8, 2012
Transparency and the Food and Drug Administration--a quantitative studyRagnar Lofstedt, Frederic Bouder, Sweta Chakraborty
International Journal of Public Health|March 20, 2023
Satisfaction With Governmental Risk Communication Both Increases and Decreases COVID-19 Mitigation BehavioursDarrick Evensen, George Warren, Frederic Bouder
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 2, 2015
Transparency in Europe: A Quantitative StudyFrederic Bouder, Dominic Way, Ragnar Löfstedt, et al.
Drug Safety|October 16, 2016
Pharmaceutical Benefit-Risk Communication Tools: A Review of the LiteratureDominic Way, Hortense Blazsin, Ragnar Löfstedt, et al.
Expert Review of Vaccines|December 21, 2012
Prioritizing polioBarbara Rath, Mohammad Ali, Chris Elemuwa, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Drug Safety|April 11, 2015
Risk communication of vaccines: challenges in the post-trust environmentFrederic Bouder
Expert Review of Clinical Pharmacology|January 16, 2014
Regulating impurities in pharmaceutical products: a tolerability of risk approach?Frederic Bouder
Expert Review of Clinical Pharmacology|January 16, 2014
Tolerability of risk approach and the management of pharmaceutical risksFrederic Bouder, Ragnar Löfstedt
Current Drug Safety|May 10, 2013
The future of risk communication and the role of the pharmaceutical industrySweta Chakraborty, Frederic Bouder
Journal of Health Communication|November 8, 2012
Transparency and the Food and Drug Administration--a quantitative studyRagnar Lofstedt, Frederic Bouder, Sweta Chakraborty
International Journal of Public Health|March 20, 2023
Satisfaction With Governmental Risk Communication Both Increases and Decreases COVID-19 Mitigation BehavioursDarrick Evensen, George Warren, Frederic Bouder
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 2, 2015
Transparency in Europe: A Quantitative StudyFrederic Bouder, Dominic Way, Ragnar Löfstedt, et al.
Drug Safety|October 16, 2016
Pharmaceutical Benefit-Risk Communication Tools: A Review of the LiteratureDominic Way, Hortense Blazsin, Ragnar Löfstedt, et al.
Expert Review of Vaccines|December 21, 2012
Prioritizing polioBarbara Rath, Mohammad Ali, Chris Elemuwa, et al.
Pageof 1